BIVI earnings analysis
What we found in BIVI's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BioVie made clinical progress, including positive SUNRISE-PD Phase 2b topline results and completion of enrollment in the ADDRESS-LC study, while continuing to pursue bezisterim across Parkinson’s disease, Alzheimer’s disease, and Long COVID and BIV201 in advanced liver disease. However, the company remains entirely pre-revenue, with FY2026 net loss rising to $22.073 million, operating cash use of $19.025 million, and cash of $8.977 million, creating substantial financing and going-concern risk. The newly certified securities class action and the underpowered Alzheimer’s Phase 3 trial add material legal and clinical uncertainty despite the recent Parkinson’s data.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Positive SUNRISE-PD Phase 2b Results
- BioVie reported positive topline results from the SUNRISE-PD Phase 2b trial in August 2026. The company said bezisterim met prespecified endpoints and that treated participants showed greater improvements than placebo across daily living, motor, and nonmotor clinical measures, supporting design of a potentially pivotal Phase 3 trial.
- Two Key Clinical Programs Enrolled
- The company completed enrollment in both major active Phase 2 programs: SUNRISE-PD enrolled through December 2025 and the ADDRESS-LC Long COVID study completed enrollment in May 2026. BioVie expects to report ADDRESS-LC topline results in late summer 2026.
- Multi-Indication Bezisterim Strategy
- BioVie is pursuing a multi-indication strategy for bezisterim across Parkinson’s disease, Alzheimer’s disease, and Long COVID, targeting estimated U.S. populations of 1 million, 6 million, and approximately 20 million adults, respectively.
- Grant-Funded Long COVID Program
- The Long COVID program is supported by a $13.1 million U.S. Department of War grant. As of June 30, 2026, the company had incurred approximately $12.9 million of program costs, and approximately $7.6 million of reimbursements were recognized against R&D expense in FY2026.
- Clinical Investment Accelerated
- The company expanded clinical investment, with R&D expense increasing to $13.962 million from $9.267 million in FY2025. Clinical studies expense rose to approximately $8.177 million from $3.660 million, primarily reflecting higher SUNRISE-PD and Long COVID activity.
- Regulatory and IP Positioning
- BioVie’s pipeline has differentiated regulatory and intellectual-property positioning: BIV201 has FDA Fast Track and Orphan Drug designations for ascites, while bezisterim is patented in the United States, Australia, Canada, Europe, and South Korea.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Certified Securities Class Action
- The securities class action materially advanced during FY2026: the court granted class certification on June 18, 2026, and the defendants answered the Second Amended Complaint on June 22, 2026. The company seeks unspecified monetary damages, has not established a reserve, and its insurance has a $2 million deductible covering the first $2 million of defense costs and damages.
- Going-Concern and Funding Risk
- BioVie remains pre-revenue and reported a $22.073 million net loss, $19.025 million of operating cash use, and only $8.977 million of cash and cash equivalents at June 30, 2026. Management states that these circumstances raise substantial doubt about the company’s ability to continue as a going concern and that additional financing is required.
- Underpowered Alzheimer’s Trial
- The Alzheimer’s Phase 3 trial remains a significant development risk: protocol deviations and cGCP violations at 15 study sites led to patient exclusions, leaving only 81 patients in the Modified Intent-to-Treat population and 57 in the Per-Protocol population versus an original design of 125 patients in each arm. The filing states that the trial was left underpowered for its primary endpoints.
- Material Equity Dilution Overhang
- Future financing could substantially dilute shareholders. At June 30, 2026, 7.542638 million common shares were outstanding, alongside 7.902037 million warrants, 2.785363 million options, and 380,000 pre-funded warrants; the company is also obligated to issue up to 180,000 additional shares upon specified milestones.
- Third-Party Clinical Execution Risk
- Clinical execution depends heavily on third parties, and the company cites prior failures at 15 study sites in its Alzheimer’s trial. BioVie relies on CROs, clinical sites, investigators, laboratories, IRBs, manufacturers, and suppliers for BIV201 and bezisterim, limiting direct control over trial conduct and data quality.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-3.05
- Segment
- Single operating segment: neurological and neurodegenerative disorders and advanced liver disease; no segment revenue disclosed.
- Segment
- Clinical studies expense: $8.177 million in FY2026 versus $3.660 million in FY2025.
- Segment
- Clinical teams expense: $5.150 million in FY2026 versus $4.479 million in FY2025.
- Segment
- General and administrative expense: $8.511 million in FY2026 versus $8.570 million in FY2025.
What they said about what is next.
No annual revenue or EPS guidance is provided. The company expects to report topline results from the ADDRESS-LC Long COVID Phase 2 study in late summer 2026 and intends to use SUNRISE-PD results to inform a potentially pivotal Phase 3 trial.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 11, 2026
- BioVie Inc. continues to struggle financially with increasing net losses and no revenue generation. The company's net loss increased to $5.3 million for Q1 2026, up from $2.8 million in Q1 2025, while R&D expenses…
- 10-K · August 15, 2025
- BioVie is a clinical-stage biopharmaceutical company focused on two principal programs: bezisterim (NE3107) for neurodegenerative indications and long COVID, and BIV201 (continuous-infusion terlipressin) for…
- 10-Q · November 13, 2024
- BioVie reported a materially smaller net loss for the three months ended September 30, 2024 of $(4,152,032) (net loss attributable to common stockholders $(4,477,073), $(0.70) per share) versus $(10,710,464) and $(2.92)…
- 10-Q · February 13, 2024
- BioVie remains a pre-revenue clinical-stage biotech with improving quarterly operating performance but clear liquidity and clinical-development risks. For the three months ended December 31, 2023 the company narrowed…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BIVI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever